Bloom Energy stock price slides as Jefferies lifts target but keeps Underperform
26 January 2026

Bloom Energy stock price slides as Jefferies lifts target but keeps Underperform

New York, Jan 26, 2026, 15:29 ET — Regular session

  • Bloom Energy shares slipped roughly 4% in afternoon trading, hovering close to the session’s low
  • Jefferies bumps up its price target yet sticks with an Underperform rating
  • Investors are zeroing in on the Feb. 5 results, searching for clues on delivery pace and capacity.

Shares of Bloom Energy Corporation slid roughly 4.3% to $138.72 in afternoon trading Monday, after earlier fluctuating between $147.60 and $138.17.

The drop matters because Bloom has turned into a quick gauge for a broader trend: data centers demanding power immediately, not down the road. As its next earnings approach, traders are taking every analyst update as a sign of how much positive news is already priced in.

Bloom’s recent surge raises a straightforward question once again. Can it produce enough systems at scale, on time, while maintaining price and margin discipline?

Jefferies raised its price target on Bloom Energy to $92 from $53 but maintained an Underperform rating. Analyst Dushyant Ailani attributed the jump to updated 2026 forecasts tied to recent orders involving American Electric Power and Quanta. He warned, however, that “peak valuations leave little room for error” ahead of the company’s earnings report in about 10 days, when investors will be watching closely for any capacity-expansion updates. Investing.com

The split screen — rising numbers paired with a still-bearish rating — keeps appearing in coverage as Bloom’s shares climb. Bulls argue that on-site generation could shorten the long wait for new grid hookups; bears remain focused on execution risks and the pace at which production can truly scale.

Bloom offers solid oxide fuel-cell systems that produce electricity on site, usually powered by natural gas or other fuels. The company’s key selling points are reliability and rapid deployment, targeting energy-intensive data centers.

Investors will be looking for the next update to clarify what “capacity” represents in concrete terms—and what impact it has on cash flow. Attention will also focus on how management explains turning sizable orders into actual deployments, and how uneven that rollout might be from one quarter to the next.

However, the situation is double-edged. Should management take a conservative stance on 2026 delivery goals or indicate increased spending to handle demand, the stock’s recent swings could flip just as fast.

Bloom announced it will report its fourth-quarter 2025 earnings after the market closes on Feb. 5. The company plans a conference call at 5:00 p.m. ET.

For now, trading will hinge on headlines — analyst updates, moves from major clients, and hints about manufacturing growth. The next key milestone is the Feb. 5 report and the guidance it brings.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 BUY

Pfizer

NYSE: PFE 93 / 100
#2 TACTICAL BUY

AMD

NASDAQ: AMD 91 / 100
#3 STRONG BUY

AerCap

NYSE: AER 90 / 100
#4 BUY ONLY ON PULLBACK

Booking Holdings

NASDAQ: BKNG 88 / 100
#5 BUY ON WEAKNESS

Visa

NYSE: V 86 / 100
View full portfolio
Editorial model selection. Not personalised advice.
Disney stock edges higher in afternoon trade — what to watch before Feb. 2 earnings
Previous Story

Disney stock edges higher in afternoon trade — what to watch before Feb. 2 earnings

Merck stock slips after report says MRK stepped back from Revolution Medicines talks
Next Story

Merck stock slips after report says MRK stepped back from Revolution Medicines talks